Levin Capital Strategies L.P. lowered its stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS – Free Report) by 17.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,459 shares of the company’s stock after selling 58,305 shares during the quarter. Levin Capital Strategies L.P.’s holdings in Alpha Tau Medical were worth $710,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently added to or reduced their stakes in DRTS. Caprock Group LLC purchased a new stake in shares of Alpha Tau Medical during the second quarter valued at about $59,000. Aptus Capital Advisors LLC increased its holdings in shares of Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. raised its position in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares during the last quarter. USAdvisors Wealth Management LLC purchased a new position in shares of Alpha Tau Medical in the 1st quarter valued at approximately $30,000. Finally, Private Advisor Group LLC acquired a new stake in Alpha Tau Medical in the 4th quarter worth approximately $176,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.
Alpha Tau Medical Trading Down 1.5 %
Shares of Alpha Tau Medical stock opened at $2.24 on Tuesday. The stock has a market cap of $156.06 million, a PE ratio of -5.46 and a beta of 0.77. The firm has a fifty day moving average price of $2.18 and a 200 day moving average price of $2.49. Alpha Tau Medical Ltd. has a 1 year low of $1.75 and a 1 year high of $3.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.66 and a quick ratio of 11.60.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on DRTS shares. Piper Sandler restated an “overweight” rating and issued a $7.00 target price on shares of Alpha Tau Medical in a research note on Thursday, August 15th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, August 20th.
Get Our Latest Stock Report on DRTS
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Featured Stories
- Five stocks we like better than Alpha Tau Medical
- Insider Trading – What You Need to Know
- Top 3 Stocks to Secure Strong Returns Through Market Uncertainty
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- How the Fed’s Rate Cuts Could Boost Bonds, Silver, and Small Caps
- What is the Australian Securities Exchange (ASX)
- Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Want to see what other hedge funds are holding DRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpha Tau Medical Ltd. (NASDAQ:DRTS – Free Report).
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.